FDA approves quizartinib for acute myeloid leukaemia
Drug Discovery World
JULY 25, 2023
The US Food and Drug Administration (FDA) has approved Daiichi Sankyo’s quizartinib (Vanflyta) for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3 internal tandem duplication (ITD)-positive.
Let's personalize your content